Speakers

Expand/Collapse

Michael Fossel
President & Founder
Telocyte

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

10:05 am | Challenging Differentiated Approach to Neurodegeneration: A Unified Systems Model for Age-Related Neurodegenerative Disease

Andreas Jeromin
Chief Scientific Officer
Cohen Veterans Bioscience

Day One

Wednesday, August 25 2021

3:40 pm | Blood-based biomarkers in AD : When the Future Becomes the Present

Chris Whelan
Associate Director & Head of Translational Genetics
Biogen

Day One

Wednesday, August 25 2021

12:40 pm | Chair Led Q&A

11:40 am | Dementia, Biomarkers and Biobanks: Applying Proteomics at Population Scale

Leslie Holsinger
Executive Vice President of Research & Development
Cortexyme

Day One

Wednesday, August 25 2021

12:40 pm | Chair Led Q&A

12:00 pm | Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial; An Ongoing Phase 2/3 Clinical Trial Assessing the Activity of Atuzaginstat in Patients with Mild to Moderate Alzheimer’s Disease

Michela Gallagher
Founder & Chief Executive Officer
AgeneBio

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial

Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial

CJ Barnum
Head of Neuroscience
INmune Bio

Day Two

Thursday, August 26 2021

12:00 pm | Chair Led Q&A; Precision Through Combination Biomarkers

11:20 am | What it Means to Demonstrate Target Engagement in Therapies that Target the Immune System: Role of Combination of Biomarkers.

10:20 am | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease

9:00 am | Biomarkers to Evaluate Therapies that Target the Immune System in Early-Stage Alzheimer’s Trials: Patient Selection, Target Engagement, & Promising Technologies

Hans Moebius
Chief Medical Officer
Athira Pharma

Day One

Wednesday, August 25 2021

3:00 pm | Chair Led Q&A

2:40 pm | Advances in Direct, Functional, Non-Invasive Biomarkers; Athira’s Utilization of ERP P300

Juli Jones
Director & Head of Disease Biology
Cyclerion Therapeutics

Chrisopher Winrow
Head of Translational Medicine
Cyclerion Therapeutics

Day Two

Thursday, August 26 2021

1:40 pm | Chair Led Q&A; Translating Biomarkers from Preclinical to Clinical Development

1:20 pm | Leading the Vanguard - Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease Therapies

Michele Vendruscolo
Chief Scientific Officer
Wren Therapeutics

Day One

Wednesday, August 25 2021

3:00 pm | Chair Led Q&A

2:20 pm | Detection & Quantification of Amyloid Beta Oligomers

Jonathan Levenson
Vice President of Translational Biology
Tiaki Therapeutics

Day One

Wednesday, August 25 2021

3:00 pm | Chair Led Q&A

2:00 pm | Using Multi-Omics Data to Identify Novel Biomarkers & Biomarker Strategies

Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics

Day One

Wednesday, August 25 2021

4:05 pm | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression

Felix Yeh
Head of Biomarkers
Alector

Day One

Wednesday, August 25 2021

12:40 pm | Chair Led Q&A

12:20 pm | Biomarker Strategies to Enable Successful Development of Immuno-Neurology Targets

Mark Frasier
Co-Chief Scientific Officer
The Michael J Fox Foundation

Day One

Wednesday, August 25 2021

4:05 pm | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression

Nicole Bjorklund
Assistant Director – Scientific Affairs
Alzheimer’s Drug Discover Foundation

Day Two

Thursday, August 26 2021

12:00 pm | Chair Led Q&A; Precision Through Combination Biomarkers

11:40 am | Emerging Biomarker Combinations for Personalized Alzheimer’s Disease Diagnosis & Treatment

Ralph Kern
President & Chief Medical Officer
BrainStorm Cell Therapeutics

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:00 am | Opening Presentation: Treating Alzheimer’s Disease as a Heterogenous Disease

Stacy Lindborg
Executive Vice President & Head of Global Clinical Research
BrainStorm Cell Therapeutics

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:00 am | Opening Presentation: Treating Alzheimer’s Disease as a Heterogenous Disease

Douglas Galasko
Associate Director
UCSD Shiley-Marcos Alzheimer’s Disease Research Center

Day Two

Thursday, August 26 2021

10:20 am | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease

9:40 am | Presenter Led Audience Discussion

9:20 am | Mapping Alzheimer Biomarkers for Context of Use With the FDA BEST (Biomarkers, Endpoints, and other Tools) Guidance

Elizabeth Somers
Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics
Eisai

Maria Maccecchini
Founder, President, CEO and Executive Board Member
Annovis Bio

Day Two

Thursday, August 26 2021

11:00 am | Presentation details to be confirmed

12:00 pm | Chair Led Q&A; Precision Through Combination Biomarkers